FDA Withdraws From Global Harmonization Group, Announces Surveys on Service Levels

The FDA has withdrawn from the Global Harmonization Working Party (GHWP) and will focus its efforts to ensure alignment of medical device international harmonization by primarily working with the International…

Continue ReadingFDA Withdraws From Global Harmonization Group, Announces Surveys on Service Levels

Rare Cancer Drugs Carry Unique FDA Postmarketing Requirements, Say Scholars

Nearly half of rare oncology drug approvals include postmarketing requirements (PMR) for drug-drug interactions (DDI), a particular concern for cancer patients who are frequently being treated for co-morbidities and palliative…

Continue ReadingRare Cancer Drugs Carry Unique FDA Postmarketing Requirements, Say Scholars